In the past week, AKBA stock has gone up by 8.77%, with a monthly gain of 24.21% and a quarterly surge of 50.48%. The volatility ratio for the week is 5.41%, and the volatility levels for the last 30 days are 5.95% for Akebia Therapeutics Inc The simple moving average for the past 20 days is 8.73% for AKBA’s stock, with a 47.28% simple moving average for the past 200 days.
Is It Worth Investing in Akebia Therapeutics Inc (NASDAQ: AKBA) Right Now?
The 36-month beta value for AKBA is at 0.70. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for AKBA is 207.21M, and currently, shorts hold a 5.77% of that float. The average trading volume for AKBA on December 03, 2024 was 1.87M shares.
AKBA) stock’s latest price update
The stock price of Akebia Therapeutics Inc (NASDAQ: AKBA) has plunged by -1.45 when compared to previous closing price of 2.13, but the company has seen a 8.77% gain in its stock price over the last five trading sessions. prnewswire.com reported 2024-12-03 that Outcomes study will assess mortality and hospitalization in patients treated with Vafseo compared to current standard of care CAMBRIDGE, Mass., Dec. 3, 2024 /PRNewswire/ — Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, announced that in late November U.S. Renal Care (USRC) enrolled the first patient in its Vafseo® (vadadustat) Outcomes In-Center Experience (VOICE) collaborative trial.
Analysts’ Opinion of AKBA
Many brokerage firms have already submitted their reports for AKBA stocks, with BTIG Research repeating the rating for AKBA by listing it as a “Buy.” The predicted price for AKBA in the upcoming period, according to BTIG Research is $4 based on the research report published on November 29, 2023 of the previous year 2023.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see AKBA reach a price target of $3.75. The rating they have provided for AKBA stocks is “Buy” according to the report published on August 28th, 2023.
Piper Sandler gave a rating of “Overweight” to AKBA, setting the target price at $4 in the report published on May 31st of the previous year.
AKBA Trading at 28.48% from the 50-Day Moving Average
After a stumble in the market that brought AKBA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -15.35% of loss for the given period.
Volatility was left at 5.95%, however, over the last 30 days, the volatility rate increased by 5.41%, as shares surge +14.86% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +62.21% upper at present.
During the last 5 trading sessions, AKBA rose by +10.10%, which changed the moving average for the period of 200-days by +46.55% in comparison to the 20-day moving average, which settled at $1.93. In addition, Akebia Therapeutics Inc saw 69.29% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AKBA starting from Hadas Nicole R., who sale 12,016 shares at the price of $1.26 back on May 13 ’24. After this action, Hadas Nicole R. now owns 651,243 shares of Akebia Therapeutics Inc, valued at $15,140 using the latest closing price.
Dahan Michel, the SVP, Chief Operating Officer of Akebia Therapeutics Inc, sale 34,840 shares at $1.26 during a trade that took place back on May 13 ’24, which means that Dahan Michel is holding 672,092 shares at $43,898 based on the most recent closing price.
Stock Fundamentals for AKBA
Current profitability levels for the company are sitting at:
- -0.2 for the present operating margin
- 0.63 for the gross margin
The net margin for Akebia Therapeutics Inc stands at -0.27. The total capital return value is set at -0.25.
Based on Akebia Therapeutics Inc (AKBA), the company’s capital structure generated -3.18 points at debt to capital in total, while cash flow to debt ratio is standing at -1.0. The debt to equity ratio resting at -0.76. The interest coverage ratio of the stock is -2.73.
Currently, EBITDA for the company is -6.87 million with net debt to EBITDA at 2.79. When we switch over and look at the enterprise to sales, we see a ratio of 2.76. The receivables turnover for the company is 5.28for trailing twelve months and the total asset turnover is 0.82. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.52.
Conclusion
In conclusion, Akebia Therapeutics Inc (AKBA) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
